Targets › RPS27
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Other, Oncology; next expected readout Jun 2027.
Component of the small ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. (UniProt, P42677)
Open in Phaseline: the race on RPS27, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eloxx Pharmaceuticals | Elx-02 80S Ribosome modulator | RPSA, RPS27, RPS6, RPS2, RPS3 | Phase 2 | Alport Syndrome, X-Linked | Jun 2027 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Ataluren 80S Ribosome modulator | RPSA, RPS27, RPS6, RPS2, RPS3 | Phase 1 | Colorectal Cancer | – |
Alport Syndrome, X-Linked (1) Colorectal Cancer (1)
small molecule (1), antibody (1)
Eloxx Pharmaceuticals (1) Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.